Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer
Background Intravesical Bacillus Calmette-Guérin (BCG) instillation is the most effective treatment for reducing intravesical recurrence in non-muscle invasive bladder cancer (NMIBC). However, due to the recent global shortage of BCG, there is an increasing need for alternative treatments. This stud...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kosin University College of Medicine
2024-12-01
|
| Series: | Kosin Medical Journal |
| Subjects: | |
| Online Access: | http://www.kosinmedj.org/upload/pdf/kmj-24-143.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846100499306119168 |
|---|---|
| author | Dong Ha Kim Taek Sang Kim Su Hwan Kang Seong Bin Kim |
| author_facet | Dong Ha Kim Taek Sang Kim Su Hwan Kang Seong Bin Kim |
| author_sort | Dong Ha Kim |
| collection | DOAJ |
| description | Background Intravesical Bacillus Calmette-Guérin (BCG) instillation is the most effective treatment for reducing intravesical recurrence in non-muscle invasive bladder cancer (NMIBC). However, due to the recent global shortage of BCG, there is an increasing need for alternative treatments. This study aimed to retrospectively compare the outcomes of patients treated with intravesical gemcitabine instillation and BCG instillation as initial treatment options for NMIBC. Methods Seventy-eight patients with NMIBC who underwent transurethral resection of bladder tumors between January 2022 and September 2023 were reviewed. Of these, 42 patients received intravesical gemcitabine instillation, and 36 patients received BCG instillation. Recurrence-free survival (RFS) was analyzed, along with tumor multiplicity, grade, T stage, size, and bladder storage time after instillation, which could influence RFS. Results The mean follow-up period was 18.7 months for the gemcitabine group and 20.6 months for the BCG group. Recurrence occurred in 46.15% of patients (52.38% in the gemcitabine group and 38.92% in the BCG group). Tumor characteristics, including multiplicity, grade, stage, and size, were not significantly different between the two groups. The mean RFS was 15.92 months in the gemcitabine group and 19.84 months in the BCG group, with no statistically significant difference (p=0.397). However, gemcitabine instillation caused more severe bladder irritation, with shorter bladder storage time. Conclusions Intravesical gemcitabine and BCG instillation yielded comparable RFS outcomes. However, gemcitabine led to more severe bladder irritation, highlighting the need for further studies to optimize its application. |
| format | Article |
| id | doaj-art-0233efe98a4545b9af74f99b3219299a |
| institution | Kabale University |
| issn | 2005-9531 2586-7024 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Kosin University College of Medicine |
| record_format | Article |
| series | Kosin Medical Journal |
| spelling | doaj-art-0233efe98a4545b9af74f99b3219299a2024-12-30T04:43:15ZengKosin University College of MedicineKosin Medical Journal2005-95312586-70242024-12-0139425425810.7180/kmj.24.1431302Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancerDong Ha Kim0Taek Sang KimSu Hwan Kang1Seong Bin Kim2 Department of Urology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea Department of Urology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea Department of Urology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, KoreaBackground Intravesical Bacillus Calmette-Guérin (BCG) instillation is the most effective treatment for reducing intravesical recurrence in non-muscle invasive bladder cancer (NMIBC). However, due to the recent global shortage of BCG, there is an increasing need for alternative treatments. This study aimed to retrospectively compare the outcomes of patients treated with intravesical gemcitabine instillation and BCG instillation as initial treatment options for NMIBC. Methods Seventy-eight patients with NMIBC who underwent transurethral resection of bladder tumors between January 2022 and September 2023 were reviewed. Of these, 42 patients received intravesical gemcitabine instillation, and 36 patients received BCG instillation. Recurrence-free survival (RFS) was analyzed, along with tumor multiplicity, grade, T stage, size, and bladder storage time after instillation, which could influence RFS. Results The mean follow-up period was 18.7 months for the gemcitabine group and 20.6 months for the BCG group. Recurrence occurred in 46.15% of patients (52.38% in the gemcitabine group and 38.92% in the BCG group). Tumor characteristics, including multiplicity, grade, stage, and size, were not significantly different between the two groups. The mean RFS was 15.92 months in the gemcitabine group and 19.84 months in the BCG group, with no statistically significant difference (p=0.397). However, gemcitabine instillation caused more severe bladder irritation, with shorter bladder storage time. Conclusions Intravesical gemcitabine and BCG instillation yielded comparable RFS outcomes. However, gemcitabine led to more severe bladder irritation, highlighting the need for further studies to optimize its application.http://www.kosinmedj.org/upload/pdf/kmj-24-143.pdfbcg vaccinegemcitabineintravesical instillationnon-muscle invasive bladder neoplasms |
| spellingShingle | Dong Ha Kim Taek Sang Kim Su Hwan Kang Seong Bin Kim Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer Kosin Medical Journal bcg vaccine gemcitabine intravesical instillation non-muscle invasive bladder neoplasms |
| title | Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer |
| title_full | Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer |
| title_fullStr | Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer |
| title_full_unstemmed | Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer |
| title_short | Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer |
| title_sort | efficacy of intravesical gemcitabine instillation compared with intravesical bacillus calmette guerin instillation for non muscle invasive bladder cancer |
| topic | bcg vaccine gemcitabine intravesical instillation non-muscle invasive bladder neoplasms |
| url | http://www.kosinmedj.org/upload/pdf/kmj-24-143.pdf |
| work_keys_str_mv | AT donghakim efficacyofintravesicalgemcitabineinstillationcomparedwithintravesicalbacilluscalmetteguerininstillationfornonmuscleinvasivebladdercancer AT taeksangkim efficacyofintravesicalgemcitabineinstillationcomparedwithintravesicalbacilluscalmetteguerininstillationfornonmuscleinvasivebladdercancer AT suhwankang efficacyofintravesicalgemcitabineinstillationcomparedwithintravesicalbacilluscalmetteguerininstillationfornonmuscleinvasivebladdercancer AT seongbinkim efficacyofintravesicalgemcitabineinstillationcomparedwithintravesicalbacilluscalmetteguerininstillationfornonmuscleinvasivebladdercancer |